Invokana

What is it?

Composition

Invokana tablets contain the active substance canagliflozin (as canagliflozin hemihydrate). The product is supplied as oral film-coated tablets in strengths such as 100 mg and 300 mg.

How to use?

Invokana is used in adults with type 2 diabetes mellitus to improve glycemic control together with diet and exercise. It can be used alone or with other glucose-lowering medicines as prescribed. In selected patients it is also used to reduce the risk of major cardiovascular events and to help slow progression of diabetic kidney disease.

How does it work?

• Route: Oral (tablet), swallow with water.
• Dose: 100 mg or 300 mg.
• Frequency: 1 time/day.
• Timing: Take in the morning; may be taken with or without food.
• Duration: Long-term daily therapy as prescribed; do not stop without medical advice.

Indications

Invokana, containing the active ingredient canagliflozin, is a prescription medication used to manage type 2 diabetes. It is used for adults who need better day-to-day glucose control alongside diet and activity, often as an add-on to other diabetes medicines. It works by helping the kidneys remove excess glucose from the blood and is also known to reduce the risk of major cardiovascular events in certain adults with type 2 diabetes.

For selected adults with type 2 diabetes, Invokana is used for outcomes that go beyond glucose numbers. It has evidence for reducing the risk of major adverse cardiovascular events (MACE), which includes heart attack, stroke, and cardiovascular death in certain high-risk populations, and it also has data supporting kidney protection in diabetic kidney disease settings. These benefits are a key reason many clinicians consider SGLT2 inhibitors earlier in the treatment pathway than they did a decade ago, especially when the patient has established cardiovascular disease or albuminuria.

Comparison

Diabetes medicines differ by where they act and what they change beyond glucose. Invokana (canagliflozin) works through the kidneys, so it can support weight reduction and blood pressure lowering in some people, and it has outcome data in cardio‑renal risk settings. GLP‑1 receptor agonists such as Ozempic act through appetite and gut hormones; many patients feel fuller, yet nausea can be a limiting factor. DPP‑4 inhibitors such as Galvus (vildagliptin) are usually weight‑neutral and well tolerated, yet their cardio‑renal outcome impact is more limited.

Combination products like INVOKAMET® and INVOKAMET® XR pair canagliflozin with metformin for convenience, which can help adherence, but metformin’s GI effects can be a barrier for some people. Older agents such as Gliclazide and Repaglinide can lower HbA1c well, yet hypoglycaemia and weight gain can become the price of that potency. Pioglitazone can improve insulin sensitivity, yet fluid retention and weight gain may limit use in people with heart failure risk.

Contraindications

• Hypersensitivity/allergy to canagliflozin
• Severe renal impairment
• Dialysis
• Active dehydration (e.g., ongoing vomiting/diarrhoea)
• Current symptoms suggestive of diabetic ketoacidosis (DKA) until evaluated
• History of diabetic ketoacidosis (DKA) unless a specialist has determined a clear and monitored plan

Not recommended for

Avoid using Invokana if any of these apply, unless your clinician has specifically advised otherwise:

• You have had an allergic reaction to canagliflozin.
• You have had diabetic ketoacidosis before, or you have symptoms that could suggest DKA (such as nausea, vomiting, abdominal pain, rapid breathing, or extreme fatigue) and have not been assessed.
• Your kidneys are severely impaired or you are on dialysis.
• You are currently dehydrated, for example from ongoing vomiting or diarrhoea.

Side effects

Common side effects:

• Genital yeast infections
• Urinary tract infections
• Increased urination
• Thirst
• Dizziness or lightheadedness (volume depletion)
• Constipation or nausea

Serious side effects (seek urgent medical care):

• Diabetic ketoacidosis (can occur with only mildly elevated glucose): nausea, vomiting, abdominal pain, rapid breathing, unusual fatigue, confusion
• Severe genital or perineal infection (Fournier’s gangrene): severe pain, tenderness, redness, swelling in the genital/perineal area, fever, feeling very unwell
• Severe allergic reaction: swelling of face/lips/tongue/throat, widespread rash, trouble breathing

Additional practical points:

• Risk of ketoacidosis increases during acute illness, fasting, or very low food intake; seek medical advice promptly if unwell.
• If ketone testing is advised, blood ketone results are generally more clinically useful than urine ketones during suspected ketoacidosis.
• People using diuretics may notice stronger early effects like dizziness due to combined fluid loss.
• Temporary genital irritation can occur; persistent pain, fever, or spreading redness needs urgent assessment.
• Plan hydration during hot weather or physically demanding work to reduce dehydration risk.

Common mistakes

• Starting on a very low‑carb diet without telling the prescriber. Ketone production rises with carb restriction, and SGLT2 inhibitors can increase DKA susceptibility in the wrong setting.
• Ignoring early thrush symptoms. Waiting a week often turns a simple infection into repeated episodes that disrupt adherence.
• Doubling doses after a “high sugar day.” This does not “catch up” safely; it raises dehydration risk and does not fix the underlying cause.
• Keeping the same insulin or sulfonylurea dose when hypos begin. With add‑on therapy, hypoglycaemia is usually driven by insulin or sulfonylureas, not Invokana.
• Continuing during vomiting, severe diarrhoea, or fever. Sick days are when dehydration and DKA risk climb fastest.
• Relying on urine glucose strips to judge control. Invokana makes urine glucose high by design, so those strips can look “worse” even as HbA1c improves.

One sentence that saves trouble: sick-day planning matters.

Doctor opinions

In clinical practice, doctors often choose Invokana when metformin alone is not enough and the patient has cardiovascular risk factors, because the mechanism is insulin‑independent and complements other agents. Endocrinologists also like that SGLT2 inhibitors can reduce glucose variability through the day, not just post‑meal peaks, which can help some patients feel less “swingy” between meals.

Many prescribers also watch the first month closely for volume depletion, genital infections, and any symptoms that could point to diabetic ketoacidosis (DKA). People who run very low carbs, skip meals, or become acutely unwell are the ones who trigger the most caution. If the patient uses insulin or a sulfonylurea, clinicians often anticipate hypoglycaemia and adjust the other drug first, because Invokana itself does not usually cause low sugar unless combined with insulin‑releasing therapy.

One more practical point doctors mention: urine glucose tests become less useful for tracking control on SGLT2 inhibitors, since the drug intentionally increases glucose in urine. Blood glucose and HbA1c remain the meaningful targets.

Frequently asked questions

How quickly does Invokana start lowering blood sugar?

Invokana begins increasing urinary glucose excretion after the first doses, so some people see lower home glucose readings within days. HbA1c changes take longer because HbA1c reflects roughly 2–3 months of average glucose. EMA assessment documents describe meaningful HbA1c reduction over weeks with consistent dosing and lifestyle measures ^[4]. In 2026 clinical practice, follow-up is often planned within the first month to address hydration, infections, and hypo risk if combined with insulin.

Can Invokana Be Taken With Insulin?

Yes, Invokana can be prescribed alongside insulin in type 2 diabetes when additional glucose lowering is needed. The main practical issue is hypoglycaemia, since insulin is the driver of low sugars when overall treatment intensity increases. Clinicians commonly pre-empt this by adjusting insulin doses and increasing glucose monitoring at the start. WHO type 2 diabetes guidance frameworks referenced in 2026 stress prioritising regimens that reduce hypoglycaemia risk while meeting targets, which supports careful insulin adjustment when adding SGLT2 inhibitors .

What happens if I miss a dose of Invokana?

Most prescribers advise taking the missed dose when you remember on the same day, then continuing your normal schedule. If it is close to the next dose, skipping the missed dose is commonly preferred to avoid doubling and dehydration. The reason is simple: taking extra does not “fix” yesterday’s readings, but it can increase urination and dizziness. For patient-facing dosing instructions, MOHAP-aligned medication guidance in the UAE typically focuses on avoiding double dosing and monitoring symptoms when therapy is resumed ^[5].

Does Invokana make you urinate more?

Yes. By blocking SGLT2, canagliflozin causes glucose to stay in the urine, and glucose pulls water with it, so urine volume can rise. Many people notice this most in the first 1–2 weeks, then it becomes less noticeable as routines adjust. Increased urination is also linked to thirst, and in hot climates it can contribute to dehydration if fluid intake is low. EMA documents list increased urination and volume depletion-related effects among expected class reactions for SGLT2 inhibitors .

Can Invokana cause weight loss?

A modest weight reduction is common with SGLT2 inhibitors because calories are lost through urinary glucose. The amount varies; it is usually not dramatic and can plateau. If weight loss is rapid, paired with nausea or abdominal pain, it needs assessment because DKA is a rare but serious possibility with this drug class. In 2026, many clinicians discuss weight change as a secondary benefit, while still prioritising HbA1c and cardio‑renal risk outcomes as the main targets .

Is Invokana used for heart and kidney protection?

In selected adults with type 2 diabetes, Invokana has evidence for reducing major cardiovascular events and for slowing progression in certain kidney disease contexts. These benefits apply to specific risk profiles, so clinicians match the choice to the person’s cardiovascular history, kidney function, and albuminuria status. International outcome-trial assessments reviewed by regulators are the basis for these indications and are reflected in prescribing practice in the UAE. MOHAP’s evidence-aligned approach means cardio‑renal benefit is often part of the prescribing conversation when the patient is eligible .

Do you offer anonymous delivery?

Front view

Side view

Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.